These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 25442767)

  • 1. Divergent understanding of health professionals regarding correct subsequent management of an asymptomatic patient with a positive faecal occult blood test and negative colonoscopy with resultant cost implications.
    Beswick L; Ting A; Macrae F; Dowling D; Hair C
    Intern Med J; 2014 Dec; 44(12a):1264-5. PubMed ID: 25442767
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
    Heresbach D; Chauvin P; Grolier J; Josselin JM
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for colorectal cancer: the cost to find an advanced adenoma.
    McGrath JS; Ponich TP; Gregor JC
    Am J Gastroenterol; 2002 Nov; 97(11):2902-7. PubMed ID: 12425566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Faecal occult blood test for colorectal cancer screening: high quality for a good price].
    van Veldhuizen H; Bonfrer JM; Kuipers EJ
    Ned Tijdschr Geneeskd; 2013; 157(16):A6330. PubMed ID: 23594877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer: which test can we afford?
    Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
    [No Abstract]   [Full Text] [Related]  

  • 9. Speaking for the evidence: colonoscopy vs computed tomographic colonography.
    Harris R
    J Natl Cancer Inst; 2010 Aug; 102(16):1212-4. PubMed ID: 20651321
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness studies fan colonoscopy debate.
    Newman L
    J Natl Cancer Inst; 2000 Nov; 92(22):1796-8. PubMed ID: 11078753
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy, effectiveness and cost-effectiveness of endoscopic screening methods.
    Brenner H
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S20-2. PubMed ID: 18368634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Position statement of the College of Surgery of Hungary about screening for colorectal cancer].
    Sebészeti Szakmai Kollégium
    Orv Hetil; 2008 Nov; 149(46):2195-6. PubMed ID: 19004739
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods and Economic Considerations: Group 1 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003. fulfillment corporate.
    Steele RJ; Gnauck R; Hrcka R; Kronborg O; Kuntz C; Moayyedi P; O'Morain C; Spicák J; Vainio H
    Endoscopy; 2004 Apr; 36(4):349-53. PubMed ID: 15057689
    [No Abstract]   [Full Text] [Related]  

  • 16. Fecal occult blood testing when colonoscopy capacity is limited.
    Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
    J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for colorectal cancer with immunochemical faecal occult blood tests.
    Faivre J; Dancourt V; Lejeune C
    Dig Liver Dis; 2012 Dec; 44(12):967-73. PubMed ID: 22898146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal occult blood testing: best option for colorectal cancer screening in Asia?
    Sharma SP
    J Natl Cancer Inst; 2008 Aug; 100(15):1056-7. PubMed ID: 18664644
    [No Abstract]   [Full Text] [Related]  

  • 20. Colorectal cancer screening: An updated review of the available options.
    Issa IA; Noureddine M
    World J Gastroenterol; 2017 Jul; 23(28):5086-5096. PubMed ID: 28811705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.